Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes.

Murphy DM, Bejar R, Stevenson K, Neuberg D, Shi Y, Cubrich C, Richardson K, Eastlake P, Garcia-Manero G, Kantarjian H, Ebert BL, Mike Makrigiorgos G.

Leukemia. 2013 Oct;27(10):2077-81. doi: 10.1038/leu.2013.160. Epub 2013 May 27. No abstract available.

2.

Evaluation of allelic strength of human TET2 mutations and cooperation between Tet2 knockdown and oncogenic Nras mutation.

Chang YI, Damnernsawad A, Allen LK, Yang D, Ranheim EA, Young KH, Zhang J, Kong G, Wang J, Liu Y, Fu HY, Yang CS, Guo J, Song H, Zhang J.

Br J Haematol. 2014 Aug;166(3):461-5. doi: 10.1111/bjh.12871. Epub 2014 Apr 3. No abstract available.

3.

NRAS mutations in de novo acute leukemia: prevalence and clinical significance.

Dunna NR, Vuree S, Anuradha C, Sailaja K, Surekha D, Digumarti RR, Rao VR, Yadav SK, Reddy R, Vishnupriya S.

Indian J Biochem Biophys. 2014 Jun;51(3):207-10.

PMID:
25204082
4.

Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression.

Pellagatti A, Roy S, Di Genua C, Burns A, McGraw K, Valletta S, Larrayoz MJ, Fernandez-Mercado M, Mason J, Killick S, Mecucci C, Calasanz MJ, List A, Schuh A, Boultwood J.

Leukemia. 2016 Jan;30(1):247-50. doi: 10.1038/leu.2015.129. Epub 2015 May 20. No abstract available.

5.

Prevalence of BRAF and NRAS mutations in fast-growing melanomas.

Nagore E, Hacker E, Martorell-Calatayud A, Traves V, Guillen C, Hayward NK, Whiteman D.

Pigment Cell Melanoma Res. 2013 May;26(3):429-31. doi: 10.1111/pcmr.12082. Epub 2013 Mar 20. No abstract available.

PMID:
23448684
6.

Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.

Schulten HJ, Salama S, Al-Ahmadi A, Al-Mansouri Z, Mirza Z, Al-Ghamdi K, Al-Hamour OA, Huwait E, Gari M, Al-Qahtani MH, Al-Maghrabi J.

Anticancer Res. 2013 Nov;33(11):4779-84.

PMID:
24222113
7.

Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia.

Shih AH, Chung SS, Dolezal EK, Zhang SJ, Abdel-Wahab OI, Park CY, Nimer SD, Levine RL, Klimek VM.

Haematologica. 2013 Jun;98(6):908-12. doi: 10.3324/haematol.2012.076729. Epub 2013 Jan 24.

8.

SETBP1 mutation analysis in 944 patients with MDS and AML.

Thol F, Suchanek KJ, Koenecke C, Stadler M, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Kade S, Löffeld P, Banihosseini S, Bug G, Ottmann O, Hofmann WK, Krauter J, Kröger N, Ganser A, Heuser M.

Leukemia. 2013 Oct;27(10):2072-5. doi: 10.1038/leu.2013.145. Epub 2013 May 7. No abstract available.

PMID:
23648668
9.

KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases.

Zebary A, Jangard M, Omholt K, Ragnarsson-Olding B, Hansson J.

Br J Cancer. 2013 Aug 6;109(3):559-64. doi: 10.1038/bjc.2013.373. Epub 2013 Jul 16.

10.

WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations.

Patnaik MM, Lasho TL, Finke CM, Gangat N, Caramazza D, Holtan SG, Pardanani A, Knudson RA, Ketterling RP, Chen D, Hoyer JD, Hanson CA, Tefferi A.

Leukemia. 2010 Jul;24(7):1283-9. doi: 10.1038/leu.2010.105. Epub 2010 May 20.

11.

Comparative analysis of BRAF, NRAS and c-KIT mutation status between tumor tissues and autologous tumor cell-lines of stage III/IV melanoma.

Knol AC, Pandolfino MC, Vallée A, Nguyen F, Lella V, Khammari A, Denis M, Puaux AL, Dréno B.

Exp Dermatol. 2015 Jan;24(1):70-3. doi: 10.1111/exd.12584. Epub 2014 Dec 8.

PMID:
25363723
12.

Rapid targeted somatic mutation analysis of solid tumors in routine clinical diagnostics.

Magliacane G, Grassini G, Bartocci P, Francaviglia I, Dal Cin E, Barbieri G, Arrigoni G, Pecciarini L, Doglioni C, Cangi MG.

Oncotarget. 2015 Oct 13;6(31):30592-603. doi: 10.18632/oncotarget.5190.

13.

Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations.

Garay T, Molnár E, Juhász É, László V, Barbai T, Dobos J, Schelch K, Pirker C, Grusch M, Berger W, Tímár J, Hegedűs B.

Pathol Oncol Res. 2015 Sep;21(4):957-68. doi: 10.1007/s12253-015-9916-9. Epub 2015 Mar 9.

PMID:
25749811
14.

Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation.

Ulivieri A, Cardillo G, Manente L, Paone G, Mancuso AP, Vigna L, Di Stasio E, Gasbarra R, Girlando S, Leone A.

Oncotarget. 2015 Aug 14;6(23):19868-79.

15.
16.

Molecular diagnosis of familial adenomatous polyposis (FAP): genotyping of adenomatous polyposis coli (APC) alleles by MALDI-TOF mass spectrometry.

Bonk T, Humeny A, Sutter C, Gebert J, von Knebel Doeberitz M, Becker CM.

Clin Biochem. 2002 Mar;35(2):87-92.

PMID:
11983341
17.

Serial determination of FLT3 mutations in myelodysplastic syndrome patients at diagnosis, follow up or acute myeloid leukaemia transformation: incidence and their prognostic significance.

Georgiou G, Karali V, Zouvelou C, Kyriakou E, Dimou M, Chrisochoou S, Greka P, Dufexis D, Vervesou E, Dimitriadou E, Efthymiou A, Petrikkos L, Dima K, Lilakos K, Panayiotidis P.

Br J Haematol. 2006 Aug;134(3):302-6. Epub 2006 Jun 20.

PMID:
16787503
18.

NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi.

Tschandl P, Berghoff AS, Preusser M, Burgstaller-Muehlbacher S, Pehamberger H, Okamoto I, Kittler H.

PLoS One. 2013 Jul 8;8(7):e69639. doi: 10.1371/journal.pone.0069639. Print 2013.

19.

[Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].

Lázár V.

Magy Onkol. 2013 Jun;57(2):96-9. doi: MagyOnkol.2013.57.2.96. Epub 2013 May 20. Hungarian.

20.

Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.

Thol F, Friesen I, Damm F, Yun H, Weissinger EM, Krauter J, Wagner K, Chaturvedi A, Sharma A, Wichmann M, Göhring G, Schumann C, Bug G, Ottmann O, Hofmann WK, Schlegelberger B, Heuser M, Ganser A.

J Clin Oncol. 2011 Jun 20;29(18):2499-506. doi: 10.1200/JCO.2010.33.4938. Epub 2011 May 16.

PMID:
21576631

Supplemental Content

Support Center